title: Real-world experience with a novel biodegradable polymer sirolimus-eluting stent: twelve-month results of the BIOFLOW-III registry.
abstract: OBJECTIVE
  We aimed to assess the safety and performance of a novel sirolimus-eluting stent with biodegradable polymer under real-world conditions.
  
  
  RESULTS
  This prospective, multicentre, observational, all-comers registry enrolled 1,356 patients. The primary endpoint was target lesion failure at 12 months: it occurred in 5.1% (95% CI: 4.0-6.4) of patients in the overall population and in 7.7% (95% CI: 5.5-10.9), 5.8% (95% CI: 4.2-8.1), 1.8% (95% CI: 0.2-11.8) and 7.2% (95% CI: 5.1-10.0) of patients with diabetes mellitus, small vessels, chronic total occlusion and acute myocardial infarction, respectively.
  
  
  CONCLUSIONS
  This novel stent platform demonstrated good clinical outcomes in an all-comers population, even in predefined high-risk groups. ClinialTrials.gov identifier: NCT01553526
authors.affiliation: Department of Cardiovascular Medicine, Universitätsklinikum Münster, Münster, Germany.
authors.forename: Johannes
authors.initials: J
authors.lastname: Waltenberger
authors.forename: Johannes
authors.initials: J
authors.lastname: Brachmann
authors.forename: Jan
authors.initials: J
authors.lastname: van der Heyden
authors.forename: Gert
authors.initials: G
authors.lastname: Richardt
authors.forename: Ole
authors.initials: O
authors.lastname: Fröbert
authors.forename: Markus
authors.initials: M
authors.lastname: Seige
authors.forename: Andrejs
authors.initials: A
authors.lastname: Erglis
authors.forename: Willem
authors.initials: W
authors.lastname: Dewilde
authors.forename: Mark
authors.initials: M
authors.lastname: Winkens
authors.forename: Christian
authors.initials: C
authors.lastname: Hegeler-Molkewehrum
authors.forename: Norbert
authors.initials: N
authors.lastname: Klein
authors.forename: Stefan
authors.initials: S
authors.lastname: Hoffmann
mesh_terms: D020341:Absorbable Implants; D000328:Adult; D000368:Aged; D002317:Cardiovascular Agents / Q000627:therapeutic use*; D003324:Coronary Artery Disease / Q000628:therapy*; D054855:Drug-Eluting Stents; D000068338:Everolimus / Q000627:therapeutic use; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D009203:Myocardial Infarction / Q000628:therapy*; D062645:Percutaneous Coronary Intervention / Q000009:adverse effects / Q000379:methods; D011446:Prospective Studies; D011474:Prosthesis Design; D012042:Registries; D020123:Sirolimus / Q000627:therapeutic use*; D016896:Treatment Outcome
chemical_list: D002317:Cardiovascular Agents; D000068338:Everolimus; D020123:Sirolimus